103196-99-2

Upstream product

• 371-41-5 4-Fluorophenol 
• 687-47-8 (S)-Ethyl lactate 
• 79-33-4 L-Lactic acid 

Downstream Products

• 103197-00-8 (R)-2-(4-fluorophenoxy)propanol 
• 60251-90-3 (R)-2-(4-fluorophenoxy)propanoic acid 
• 1134785-12-8 4-amino-6-fluoro-2(R)-methylchroman-4-carboxylic acid 
• 102916-95-0 (2R,4S)-6-fluoro-2-methylspiro[chroman-4,4’-imidazolidine]-2’,5’-dione 
• 1134785-09-3 (4R,S)-2,3-dihydro-6-fluoro-2(R)-methylspiro<4H-benzopyran-4,4'-2'-phenyloxazolidin>-5'-one 
• 1134785-08-2 (R,S)-N-benzoyl-2-((2R)-1-bromopropoxy)-5-fluorophenylglycine 
• 103197-01-9 (R)-1-bromo-2-(4'-fluorophenoxy)propane 

Relevant academic research and scientific papers

TOPICAL TREATMENT OF CATARACTS IN DOGS

The topical treatment of cataracts in dogs is a composition having an aldose reductase inhibitor (ARI) in a topical carrier. The ARI is preferably 2R,4S-6-fluoro-2-methyl-spiro[chroman-4,4'-imidazolidine]-2',5'-dione, referred to as 2R-methyl sorbinil. Th

Topical treatment of cataracts in dogs

The topical treatment of cataracts in dogs is a composition having an aldose reductase inhibitor (ARI) in a topical carrier. The ARI is preferably 2R,4S-6-fluoro-2-methyl-spiro[chroman-4,4′-imidazolidine]-2′,5′-dione, referred to as 2R-methyl sorbinil, ha

PROCESS FOR PREPARING (R)-ARYLOXYPROPIONIC ACID ESTER DERIVATIVES

The present invention relates to a method for preparing optically active (R)-aryloxypropionic acid ester derivatives, and more particularly to a method for preparing (R)- aryloxypropionic acid ester derivatives with high optical purity and good yield at low cost from phenol derivatives with various substituted functional groups and (S)-alkyl O-arylsulfonyl lactates.

Process for the production of asymmetric hydantoins

An improved process for preparing (4S)-6-fluorospiro-[chroman-4,4''-imidazolidine]-2'',5''-dione (sorbinil) or its (2R)-methyl derivative (2-methylsorbinil) is disclosed herein, starting from p-fluorophenol in each instance. The final products obtained ha

Hydroxyacetic acid derivatives for the treatment of diabetic complications

Racemic and chiral (2R,4R)-4-c-hydroxy-2-4-(substituted)chroman(and thiochroman)-4-acetic acids and their pharmaceutically acceptable salts, their use in the treatment of diabetic complications and intermediates therefor.